JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

JNJ

172.24

-0.77%↓

ABBV

197.9

+0.31%↑

AZN

74.9

+1.11%↑

NVS

119.11

+0.89%↑

ABT

129.76

-1.11%↓

Search

Innoviva Inc

Avatud

SektorTervishoid

19.73 -0.3

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.39

Max

19.74

Põhinäitajad

By Trading Economics

Sissetulek

-67M

-47M

Müük

-3.2M

89M

P/E

Sektori keskmine

51.694

34.393

Kasumimarginaal

-52.559

Töötajad

127

EBITDA

-63M

-27M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+85.75% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-9.3M

1.2B

Eelmine avamishind

20.03

Eelmine sulgemishind

19.73

Uudiste sentiment

By Acuity

100%

0%

364 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Innoviva Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2025, 17:49 UTC

Suurimad hinnamuutused turgudel

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. aug 2025, 17:18 UTC

Suurimad hinnamuutused turgudel

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. aug 2025, 16:25 UTC

Tulu

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. aug 2025, 20:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. aug 2025, 20:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. aug 2025, 20:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement 2Q Rev $25.8M >EXOD

11. aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. aug 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. aug 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

BBVA Says Sabadell Offer Remains in Effect

11. aug 2025, 16:26 UTC

Omandamised, ülevõtmised, äriostud

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Announced TSB Sale on July 1

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Võrdlus sarnastega

Hinnamuutus

Innoviva Inc Prognoos

Hinnasiht

By TipRanks

85.75% tõus

12 kuu keskmine prognoos

Keskmine 36.5 USD  85.75%

Kõrge 55 USD

Madal 21.5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Innoviva Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

4

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

18.57 / 18.75Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

364 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.